The Role of Bladder Epicheck Test In Follow-Up of Patients with Non-Muscle Invasive Bladder Cancer

Mauro Ragonese, Luca Di Gianfrancesco, Giuseppe Palermo, Francesco Pierconti, Maurizio Martini, Massimiliano Foti, Pierfrancesco Bassi, Marco Racioppi

Research output: Contribution to journalArticle


The need of new non-invasive biomarkers for diagnosis and follow-up of non-muscle invasive bladder cancer is well-known in urological community. The methylation test such as Epicheck could overcome the limits of urinary cytology, particularly in patients treated with Endo vesical therapy. According to our results this test could be included as an adjunctive tool in follow-up of patients.Introduction: EpiCheck is a new urinary test that analyses DNA methylation biomarkers in order to identify high-risk urothelial cancer Materials and methods: A prospective single centre study was performed. We analysed Epicheck results in a population of 231 patients in follow-up for non-muscle invasive bladder cancer. The primary endpoint was to evaluate sensitivity and specificity of Epicheck in detecting any type of bladder cancer recurrence. The secondary endpoint was to evaluate specificity and sensitivity of Epicheck in patients with high-risk recurrence and in patients recently treated with endovesical therapy (< 3 months). Results: Negative predictive value (NPV) for cytology was 83 % while for bladder Epicheck it was 89 %, while positive predictive value (PPV) was 67 % and 73 % for cytology and Epicheck respectively. Considering only high grade non muscle invasive bladder cancer the sensitivity of Epicheck was 91 % and for cytology was 81 %, specificity was 85 % and 83 % and negative predictive value of Epicheck outreached 96 % compared to 92 % of cytology. Among patients with an ongoing or recent endovesical treatment it appears that sensitivity of Epicheck was 88% % compared to 73 % of cytology, specificity was 97 % and 85 % and NPV was 92 % compared to 82 % for cytology. Conclusion: The EpiCheck (test showed very high diagnostic values, higher than the currently, gold standard. The test might clinically improve the BCa management in terms of, reduced number of inconclusive/suspicious reports of cytology and endoscopy, reduced number of further examinations, reduced associated patient and economic (C) 2022 Elsevier Inc. All rights reserved.
Original languageEnglish
Pages (from-to)271-275
Number of pages5
JournalClinical Genitourinary Cancer
Publication statusPublished - 2022


  • Epicheck
  • High risk
  • Methylation
  • Non-invasive test for bladder cancer


Dive into the research topics of 'The Role of Bladder Epicheck Test In Follow-Up of Patients with Non-Muscle Invasive Bladder Cancer'. Together they form a unique fingerprint.

Cite this